CD19 and neoplasm: Among the enrolled 13 patients, case 1 achieved CR status by receiving two separate CAR T-cell products (CD22 and CD19 CAR T-cells) “cocktail” treatment before enrollment, and case 10 also was MRI negative, which attributed to tumor-sensitive chemotherapy, both of the above patients received our protocol therapy for further consolidation, and maintained clinical efficacy without recurrence until the last visit.